Latest CYP2C19 Stories
Researchers have identified the first genetic variations linked to race that begin to explain a higher risk of death among some African American and Caucasian patients taking the anti-clotting drug clopidogrel (Plavix) after a heart attack.
Rapid CYP2C19 Testing for Personalized Antiplatelet Therapy in 600-Patient Clinical Trial with Spartan Bioscience (PRWEB) March 18, 2014 Spartan Bioscience
Rapid CYP2C19 Testing for Heart Attack Patients Using Antiplatelet Drugs in 150-Patient Clinical Trial With Spartan Bioscience Ottawa, Ontario (PRWEB) December
Spartan Bioscience announces 2,000-patient clinical trial of rapid DNA testing for heart attack patients using antiplatelet drugs. Ottawa, Ontario (PRWEB) November
Sample-to-result system has FDA 510(k) clearance and provides CYP2C19 test results in 60 minutes. Ottawa, Ontario (PRWEB) November 19, 2013 Spartan Bioscience
Developed in Canada and conducted by researchers from the University of Ottawa Heart Institute, in partnership with Spartan Bioscience, the world's first bedside genetic test has received acknowledgment by The Lancet, the world's leading general medical journal.
Although the U.S. Food and Drug Administration (FDA) has recommended that a certain type of genetic testing (for the genotype CYP2C19) be considered before prescribing the drug clopidogrel to identify individuals who may be less responsive to the medication, a review and analysis of previous studies did not find an overall significant association between the CYP2C19 genotype and cardiovascular events.
- An armed gangster.